Evidence map›Paper›PMID 32386320›Full record

ArticleNeuro-oncology2020

Adult diffuse glioma GWAS by molecular subtype identifies variants in D2HGDH and FAM20C.

Jeanette E Eckel-Passow, Kristen L Drucker, Thomas M Kollmeyer, Matt L Kosel, Paul A Decker, Annette M Molinaro, Terri Rice, Corinne E Praska, Lauren Clark, Alissa Caron and 15 more

Open access · bronzeAbstract read
In one paragraph

Article in Neuro-oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 2 pooled it
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 2 syntheses or guidelines pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Glioma.Nature reviews. Disease primers · 2024
    Review
  17. Genome-wide Polygenic Risk Scores Predict Risk of Glioma and Molecular Subtypes.medRxiv : the preprint server for health sciences · 2024
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 3 institutions in 1 country.

Jeanette E Eckel-PassowDivision of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota.
Kristen L DruckerDivision of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota.
Thomas M KollmeyerDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.
Matt L KoselDivision of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota.
Paul A DeckerDivision of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota.
Annette M MolinaroDepartment of Neurological Surgery, University of California San Francisco (UCSF), San Francisco, California.
Terri RiceDepartment of Neurological Surgery, University of California San Francisco (UCSF), San Francisco, California.
Corinne E PraskaDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.
Lauren ClarkDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.
Alissa CaronDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.
Alexej AbyzovDivision of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota.
Anthony BatzlerDivision of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota.
Jun S SongDepartment of Physics, Carl R. Woese Institute for Genomic Biology, University of Illinois at Urbana-Champaign, Champaign, Illinois.
Melike PekmezciDepartment of Pathology, University of California San Francisco, San Francisco, California.
Helen M HansenDepartment of Neurological Surgery, University of California San Francisco (UCSF), San Francisco, California.
Lucie S McCoyDepartment of Neurological Surgery, University of California San Francisco (UCSF), San Francisco, California.
Paige M BracciDivision of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota.
Joseph WiemelsDepartment of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California.
John K WienckeDepartment of Neurological Surgery, University of California San Francisco (UCSF), San Francisco, California.
Stephen FrancisDepartment of Neurological Surgery, University of California San Francisco (UCSF), San Francisco, California.
Terry C BurnsDepartment of Neurologic Surgery, Mayo Clinic, Rochester, Minnesota.
Caterina GianniniDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.
Daniel H LachanceDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.
Margaret WrenschDepartment of Neurological Surgery, University of California San Francisco (UCSF), San Francisco, California.
Robert B JenkinsDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.
Mayo Clinic · USUniversity of California, San Francisco · USUniversity of Illinois Urbana-Champaign · US

Funding

Translational InformaticsP30CA082103 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Kate Taylor Shumate · 1999 to 2026
$209.7M
UCSF CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTEUL1RR024131 · NCRR · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JOHNSTON, S. CLAIBORNE · 2006 to 2011
$111.2M
Tissue CoreP50CA097257 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Susan M Chang · 2002 to 2026
$57.4M
Targeted MV-CEA as a Potent Antitumor Agent against GBMP50CA108961 · NCI · MAYO CLINIC ROCHESTER · PI O'NEILL, BRIAN PATRICK · 2004 to 2015
$22.5M
GENETIC EPIDEMIOLOGY OF MALIGNANT GLIOMAR01CA052689 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WIENCKE, JOHN K., WRENSCH, MARGARET R. · 1991 to 2015
$20.5M
International Case Control Study of Malignant GliomaR01CA139020 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BONDY, MELISSA L. · 2010 to 2015
$16.0M
Training in Molecular& Genetic Epidemiology of CancerR25CA112355 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WITTE, JOHN S. · 2005 to 2018
$6.5M
Immune epigenetic biomarkers of survival in glioma epidemiologyR01CA207360 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WIENCKE, JOHN K. · 2017 to 2021
$3.8M
UNDERSTANDING THE INTERACTIONS BETWEEN GERMLINE AND SOMATIC ALTERATIONS in the PATHOGENESIS OF GLIOMASR01CA230712 · NCI · MAYO CLINIC ROCHESTER · PI JENKINS, ROBERT B. · 2018 to 2022
$3.3M
Biomarkers of survival in glioma epidemiologyR01CA126831 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WIENCKE, JOHN K. · 2008 to 2013
$2.5M
Novel Tree-based Statistical Methods for Cancer Risk PredictionR01CA163687 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MOLINARO, ANNETTE M · 2012 to 2015
$1.3M
Identification of 9p and 20q Germline Alterations in Glioblastoma PathogenesisRC1NS068222 · NINDS · MAYO CLINIC ROCHESTER · PI JENKINS, ROBERT B. · 2009 to 2010
$984k
NCCDPHP CDC HHS NU58DP006344NCI NIH HHS HHSN261201800009CNCI NIH HHS HHSN261201800009INCI NIH HHS HHSN261201800015CNCI NIH HHS HHSN261201800015INCI NIH HHS HHSN261201800032CNCI NIH HHS HHSN261201800032INCI NIH HHS P30 CA082103NCI NIH HHS P50 CA097257NCI NIH HHS P50 CA108961NCI NIH HHS R01 CA052689NCI NIH HHS R01 CA126831NCI NIH HHS R01 CA139020NCI NIH HHS R01 CA163687NCI NIH HHS R01 CA207360NCI NIH HHS R01 CA230712NCI NIH HHS R25 CA112355NCRR NIH HHS UL1 RR024131NINDS NIH HHS RC1 NS068222
6 · The paper itself

Abstract

backgroundTwenty-five germline variants are associated with adult diffuse glioma, and some of these variants have been shown to be associated with particular subtypes of glioma. We hypothesized that additional germline variants could be identified if a genome-wide association study (GWAS) were performed by molecular subtype.

methodsA total of 1320 glioma cases and 1889 controls were used in the discovery set and 799 glioma cases and 808 controls in the validation set. Glioma cases were classified into molecular subtypes based on combinations of isocitrate dehydrogenase (IDH) mutation, telomerase reverse transcriptase (TERT) promoter mutation, and 1p/19q codeletion. Logistic regression was applied to the discovery and validation sets to test for associations of variants with each of the subtypes. A meta-analysis was subsequently performed using a genome-wide P-value threshold of 5 × 10-8.

resultsNine variants in or near D-2-hydroxyglutarate dehydrogenase (D2HGDH) on chromosome 2 were genome-wide significant in IDH-mutated glioma (most significant was rs5839764, meta P = 2.82 × 10-10). Further stratifying by 1p/19q codeletion status, one variant in D2HGDH was genome-wide significant in IDH-mutated non-codeleted glioma (rs1106639, meta P = 4.96 × 10-8). Further stratifying by TERT mutation, one variant near FAM20C (family with sequence similarity 20, member C) on chromosome 7 was genome-wide significant in gliomas that have IDH mutation, TERT mutation, and 1p/19q codeletion (rs111976262, meta P = 9.56 × 10-9). Thirty-six variants in or near GMEB2 on chromosome 20 near regulator of telomere elongation helicase 1 (RTEL1) were genome-wide significant in IDH wild-type glioma (most significant was rs4809313, meta P = 2.60 × 10-10).

conclusionsPerforming a GWAS by molecular subtype identified 2 new regions and a candidate independent region near RTEL1, which were associated with specific glioma molecular subtypes.

Indexed as

Brain NeoplasmsGliomaAdultAlcohol OxidoreductasesCasein Kinase IExtracellular Matrix ProteinsFemaleGenome-Wide Association StudyHumansIsocitrate DehydrogenaseMaleMiddle AgedMutationTelomeraseAlcohol OxidoreductasesCasein Kinase ID2HGDH protein, humanExtracellular Matrix ProteinsFAM20C protein, humanIsocitrate DehydrogenaseTelomeraseallergyglioblastomaGWAS gliomamolecular subtype

Identifiers

PMID32386320
PMCPMC7690366
OpenAlexW3020931461

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.